Neurological abnormalities specialist Wave Neuroscience said on Thursday that it has closed the brain treatment technology asset purchase agreement with Newport Brain Research Laboratory (NBRL) for an undisclosed amount.
Under the terms of the agreement, Wave Neuroscience purchased substantially all of the assets from the various onshore and offshore holding companies under NBRL.
In conjunction with the acquisition, key NBRL personnel were appointed to new roles at Wave Neuroscience.
Since June, Wave Neuroscience has pledged more than USD500,000 of free treatments to US military members.
According to Wave Neuroscience, its research revolves around the premise that the brain can be treated by non-pharmaceutical and non-surgical means. It offers a personalised treatment platform for addressing neurological abnormalities and has treated more than 7,000 patients using its patented, non-invasive, drug-free MeRT process, which is licensed by a network of independently owned medical facilities.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval